Meet Tom Cirrito, serial entrepreneur and CEO of Filament BioSolutions, Biotagenics and Immunovent. He is also the CEO of AGelity BioMechanics, the first start up company out of Hospital for Special Surgery. Dr. Cirrito previously served as Vice President of Research and Development and Director of Business Development at Stemline Therapeutics (NASDAQ: STML) since March 2012. Dr. Cirrito joined Stemline in 2005 as the second full-time employee, and was responsible for business development, preclinical, intellectual property, manufacturing, analytical, and operations. Prior to joining Stemline, Dr. Cirrito was a biopharmaceuticals equities analyst at Piper Jaffray, where he covered large and small cap biotechnology companies. Previously, he was a life sciences consultant for A.G. Edwards Capital Partners, a venture capital group. Dr. Cirrito received a B.A. in Biological Sciences and a Ph.D. in Immunology from Washington University (St. Louis, Missouri). He currently serves on the Scientific and Business Advisory Board of the Alzheimer's Drug Discovery Foundation. He serves as an investor, mentor and Board Member to early stage biotechnology and health care companies. He has published in a wide variety of scientific fields and is the inventor on numerous technologies.